Similarly, the price-to-free-cash-flow ratio is significantly higher at 67.16x, compared with the peer group average of 31.96x.

FORBES: Momentum Players Have Lots To Like About Haemonetics

However, the price-to-free-cash-flow ratio looks attractive at 19.29x, a roughly 13.8% discount to the peer group average of 22.37x.

FORBES: ResMed Breathes Easy In Rarefied Air

The theme running through these properties is low to moderate price-earnings ratios, impeccable balance sheet strength, high free cash flow generation and the capacity to indulge in financial engineering in the form of share buybacks, dividends and deal activity.

FORBES: A Handful Of One-Decision Stocks Live On